ClinicalTrials.gg
CompletedNCT06181292Updated Nov 17, 2026

Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine

A Phase 2/3 interventional study of PHH-1V81 and Comirnaty Omicron XBB1.5 in SARS-CoV2 Infection, sponsored by Hipra Scientific, S.L.U. Completed at 10 sites in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hipra Scientific, S.L.U · Phase 2/3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
913
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.

Enrollment
39th of 254
913 · median 132
Started
2023
with 21 others
Phase 2/3
25 of 401
1 open now
Registered
377th of 401
by date
Lead sponsor
7 of 401
Hipra Scientific, S.L.U

Among the 401 studies in COVID-19 with a site in Spain, this one is the 39th largest by enrollment of the 254 interventional ones that give a count, is one of 22 that started in 2023, is one of 25 in phase 2/3, and was the 377th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in COVID-19 with a site in Spain, or all of them as a file.
02

Study summary

This is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tolerability and immunogenicity of a booster vaccination with a recombinant protein receptor binding domain (RBD) fusion homodimer of XBB.1.16 adapted candidate against SARS-CoV-2 developed by HIPRA (PHH-1V81).

Read the detailed description

This is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tolerability and immunogenicity of a booster vaccination with a recombinant protein receptor binding domain (RBD) fusion homodimer of XBB.1.16 adapted candidate against SARS-CoV-2 developed by HIPRA (PHH-1V81).

Approximately 612 participants who have received a primary scheme with an EU-approved mRNA vaccine (two doses) and at least one booster dose of an EU-approved mRNA vaccine against COVID-19, will be randomly assigned to the following two treatment arms in a PHH-1V81 : Comirnaty (Omicron XBB.1.5) 2:1 ratio:

  • PHH-1V81 vaccine arm: Approximately 408 adults will receive a booster dose of PHH-1V81 (HIPRA adapted vaccine).
  • Comirnaty vaccine arm: Approximately 204 adults will receive a booster dose of Comirnaty Omicron XBB.1.5.

Participants will be stratified before randomisation by age group (approximately 10% of adults ≥60 years old), and by number of doses previously received.

All participants will receive a booster dose of PHH-1V81 or Comirnaty Omicron XBB.1.5 at Day 0 and will be followed for 6 months. All subjects will be closely observed for 15 minutes after vaccination on site.

03

Conditions studied

  • SARS-CoV2 Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 or older at Day 0
  • Are willing and able to sign the and can comply with all study visits and procedures
  • Participant must have received a primary scheme of an EU-approved mRNA vaccine (2 doses) and at least one booster dose with an EU-approved mRNA vaccine. Last booster dose must have been administered at least 6 months before Day 0.
  • Having a negative Rapid Antigen Test for COVID-19 at Day 0 prior to vaccination.
  • Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with pre-existing chronic and stable diseases (non-), if these are stable and well-controlled according to the investigator's judgment.
  • Uses an accepted method of

Exclusion criteria

Exclusion Criteria:

  • Participant with an acute illness with fever ≥ 38.0°C at Day 0 or within 24 hours prior to vaccination. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator
  • Participant with a medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Participant with history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention
  • individuals defined as those with primary and secondary immune deficiencies and those receiving chemotherapy or immunosuppressant drugs other than and glucocorticoids (maximum 30mg/day of prednisone, or equivalent, by any administration route for a maximum of 30 consecutive days), within 90 days prior to vaccination
  • Participant with a bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
  • Have receipt of blood-derived immune globulins, blood, or blood-derived products in the past 3 months
  • Participation in other studies involving study intervention if last dose is within 28 days prior to screening and/or it is planned to receive during study participation
  • Received any non-study vaccine within 14 days before or after screening. For live or attenuated vaccines, 4 weeks before or after screening
  • Received any COVID-19 vaccines other than EU-approved mRNA vaccines
  • Received any Omicron XBB adapted vaccine before Day 0
  • COVID-19 infection diagnosed in the previous 6 months before Day 0. History of COVID-19 infections is allowed
  • History of a diagnosis or other conditions that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
913 participants (actual)

Study arms

  • Experimental
    PHH-1V81

    One dose of 40ug of PHH-1V81, administered intramuscularly

    Biological: PHH-1V81

  • Active comparator
    Comirnaty Omicron XBB1.5

    One dose of 30ug of Comirnaty Omicron XBB1.5, administered intramuscularly

    Biological: Comirnaty Omicron XBB1.5

Interventions

  • BiologicalPHH-1V81

    booster of PHH-1V81

  • BiologicalComirnaty Omicron XBB1.5

    booster of Comirnaty Omicron XBB1.5

06

What researchers measure

Primary outcomes

  1. Number, percentage and characteristics of solicited local and systemic AEs, unsolicited AEs, SAEs, AESIs and MAAEs

    To assess the safety and tolerability of a PHH-1V81 booster in adults who previously received primary vaccination and at least one booster dose of an EU-approved mRNA vaccine

    Time frame: 0, 7, 14, 91 and 182 days post-vaccination

  2. Neutralising antibody titers of PHH-1V81 booster at Day 0 and 14

    To determine and compare the changes in immunogenicity measured by pseudovirus neutralisation assay (PBNA) against Omicron XBB.1.16 variant at Baseline and Day 14 in the PHH-1V81 vaccine arm versus the Comirnaty arm.

    Time frame: 0 and 14 days post-vaccination

Secondary outcomes

  1. Neutralising antibody titers of PHH-1V81 booster at Day 91 and 182

    To determine and compare the changes in immunogenicity measured by PBNA against Wuhan, Omicron BA.1 and Omicron XBB.1.5 at Baseline and at Days 14, 91 and 182, and Omicron XBB.1.16 at Days 91 and 182, after vaccination in the PHH-1V81 vaccine arm vs. the Comirnaty arm.

    Time frame: 91 and 182 days post-vaccination

  2. Total binding antibody titers of PHH-1V81 booster at Days 0, 14, 91 and 182

    To evaluate and compare the immunogenicity measured by means of total antibody against Receptor Binding Domain of the Spike protein of SARS-CoV-2, measured by an electrochemiluminescence immunoassay (ECLIA) at Baseline and at Days 14, 91 and 182 in the PHH-1V81 vaccine arm vs the Comirnaty arm.

    Time frame: 0, 14, 91 and 182 days post-vaccination

07

Study locations

10 sites
  • Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital HM Delfos
    Barcelona, Barcelona 08023, Spain
  • CAP Centelles
    Centelles, Barcelona 08540, Spain
  • Hospital Josep Trueta
    Girona, Girona 17001, Spain
  • Hospital HM Sanchinarro
    Madrid, Madrid 28050, Spain
  • Hospital Quironsalud Madrid
    Madrid, Madrid 28223, Spain
  • Hospital HM Puerta del Sur
    Móstoles, Madrid 28938, Spain
  • Hospital Regional de Málaga
    Málaga, Málaga 29010, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, Valencia 46010, Spain
  • Hospital Universitario de Cruces
    Barakaldo, Vizcaya 48903, Spain
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jun 2024, 7 months.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 7 months is below that.

Counting every sponsor, half of 169 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2023
First posted
Dec 26, 2023
StartActual
Nov 15, 2023
Primary completionActual
Jun 17, 2024
CompletionActual
Jun 17, 2024
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06181292
Lead sponsor
Hipra Scientific, S.L.U
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Nov 15, 2023
Primary completion
Jun 17, 2024
Completion
Jun 17, 2024
Last update
Nov 17, 2026

Study contacts

Teresa Prat
study director · Hipra Scientific, S.L.U

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion